Carcinoid Tumor Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Funding
• Clinical Trials

Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
Conditions:   Advanced Neuroendocrine Neoplasm;   Carcinoid Syndrome Interventions:   Biological: Retifanlimab;   Drug: Telotristat Ethyl Sponsor:   M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 2, 2021 Category: Research Source Type: clinical trials

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
Conditions:   Neuroendocrine Tumors;   Carcinoid Syndrome;   Diarrhea Interventions:   Drug: Telotristat ethyl;   Drug: Peptide Receptor Radionuclide Therapy;   Other: Placebo Sponsors:   Pashtoon Kasi, MD, MS;   TerSera Therapeutics LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2021 Category: Research Source Type: clinical trials